Understand the source comparison
Best Peptides to Stop Sugar Cravings Ranked: Clinical vs. Practical Comparison
Semaglutide GLP-1 receptor agonist. Delays gastric emptying, suppresses ghrelin, reduces dopamine reward signaling 5–7 days; weekly subcutaneous injection STEP-1 trial: 47% reduction in dessert intake frequency, 38% reduction in snacking vs baseline (68 weeks,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide
- GLP-1 receptor agonist. Delays gastric emptying, suppresses ghrelin, reduces dopamine reward signaling
- 5–7 days; weekly subcutaneous injection
- STEP-1 trial: 47% reduction in dessert intake frequency, 38% reduction in snacking vs baseline (68 weeks, n=1,961)
- Nausea in 30–45% during dose escalation; requires 20-week titration to therapeutic dose
- Strongest evidence, longest half-life, best for sustained craving suppression
- Tirzepatide
- Dual GIP/GLP-1 agonist. Activates incretin pathways and may reduce glucose-driven lipogenesis
- 5 days; weekly subcutaneous injection
- SURMOUNT-1: 20.9% mean body weight loss, qualitative reports of reduced 'food noise' and dessert appeal (72 weeks, n=2,539)
- Higher cost than semaglutide; similar GI side effects during titration
- Higher efficacy for weight loss, craving data emerging but strong anecdotal support
- Hexarelin
- Ghrelin receptor antagonist. Blocks hunger hormone signaling at GHSR1a
- 30–45 minutes; requires multiple daily doses
- Preclinical rodent studies: 50–60% reduction in food-seeking behavior during caloric restriction (Max Planck Institute)
- Short half-life limits practicality; human craving data sparse; primarily studied for cardioprotection
- Mechanism is sound, but dosing impractical outside research settings
- MC4R Agonists (Setmelanotide)
- Melanocortin-4 receptor activation. Restores leptin sensitivity, reduces hedonic eating
- 24 hours; daily subcutaneous injection
- Rhythm Pharma Phase 3: 25.6% weight loss in genetic obesity, reduced food-seeking noted in secondary endpoints
- FDA-approved only for rare genetic conditions (POMC, LEPR deficiency); not available for general use
- Strongest for leptin-resistant individuals, but access severely restricted
- PYY Analogs
- Satiety hormone mimetic. Extends postprandial fullness
- 1–2 hours; requires frequent dosing
- Obesity 2019: 15–20% reduction in ad libitum intake in normal-weight subjects; effect blunted in obese participants
- Inconsistent efficacy in metabolically compromised individuals; short duration of action
- Works in lean populations, less reliable for those with existing metabolic dysfunction